Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.
The annual meeting of the American Psychiatric Association focuses on a variety of topics, including those on psychopharmacology. The latest developments are typically those found in the New Research sections, which is where this summary will focus.
University of Miami, Department of Psychiatry & Behavioural Sciences, Miami, FL, USA. pgoodnick@aol.com
P J
PJ
Goodnick
D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy; D015283:Citalopram / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D020902:Hypericum / Q000627:therapeutic use; D000077152:Olanzapine; D008517:Phytotherapy; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010946:Plants, Medicinal; D011570:Psychiatry; D011619:Psychotropic Drugs / Q000494:pharmacology*; D012958:Societies, Scientific; D013739:Testosterone / Q000627:therapeutic use; D014481:United States
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D015283:Citalopram; D001569:Benzodiazepines; D010890:Pirenzepine; D013739:Testosterone; D000077152:Olanzapine